Gail J Roboz

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi request reprint Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia
    G J Roboz
    Division of Hematology and Oncology, Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Lymphoma 43:1951-5. 2002
  2. doi request reprint Novel approaches to the treatment of acute myeloid leukemia
    Gail J Roboz
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Hematology Am Soc Hematol Educ Program 2011:43-50. 2011
  3. ncbi request reprint International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia
    Gail J Roboz
    Gail J Roboz, Weill Cornell Medical College and the New York Presbyterian Hospital Todd Rosenblat, Columbia University Medical Center, New York, NY Martha Arellano, Winship Cancer Institute at Emory University Scott R Solomon, The Blood and Marrow Transplant Group of Georgia, Atlanta, GA Jessica K Altman, Francis J Giles, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL Casey O Connell, University of Southern California Norris Comprehensive Cancer Center and Hospital, Los Angeles, CA Marco Gobbi, Azienda Ospedaliera Universitaria San Martino, University of Genoa, Genoa, Italy Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain Arnaud Pigneux, Centre Hospitalier Universitaire de Bordeaux Hôpital Haut Lévêque, Pessac Norbert Vey, L Institut Paoli Calmettes, Marseilles, France Robert Hills, Cardiff University School of Medicine, Cardiff, United Kingdom Tove Flem Jacobsen, Athos Gianella Borradori, Øivind Foss, and Sylvia Vetrhus, Clavis Pharma ASA, Oslo, Norway
    J Clin Oncol 32:1919-26. 2014
  4. doi request reprint Current treatment of acute myeloid leukemia
    Gail J Roboz
    Leukemia Program, Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, New York 10065, USA
    Curr Opin Oncol 24:711-9. 2012
  5. pmc Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
    Gail J Roboz
    Leukemia Program, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10065, United States
    Leuk Res 36:407-12. 2012
  6. doi request reprint Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemia
    Gail J Roboz
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Semin Hematol 45:S22-4. 2008
  7. doi request reprint Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia
    Gail J Roboz
    Leukemia Program, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
    Cancer 113:2504-11. 2008
  8. doi request reprint Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome
    Gail J Roboz
    Leukemia Program, Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Res 35:522-5. 2011
  9. doi request reprint Acute myeloid leukemia stem cells: seek and destroy
    Gail J Roboz
    Weill Medical College of Cornell University, The New York Presbyterian Hospital, 520 East 70th Street, New York, NY 10021, USA
    Expert Rev Hematol 2:663-72. 2009
  10. ncbi request reprint Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma
    Gail J Roboz
    Division of Hematology Oncology, Leukemia Program, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Res 31:1141-4. 2007

Detail Information

Publications28

  1. ncbi request reprint Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia
    G J Roboz
    Division of Hematology and Oncology, Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Lymphoma 43:1951-5. 2002
    ..In conclusion, in patients with relapsed/refractory AML, gemtuzumab ozogamicin has a comparable response rate to single-agent chemotherapy and may offer a more favorable toxicity profile...
  2. doi request reprint Novel approaches to the treatment of acute myeloid leukemia
    Gail J Roboz
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Hematology Am Soc Hematol Educ Program 2011:43-50. 2011
    ....
  3. ncbi request reprint International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia
    Gail J Roboz
    Gail J Roboz, Weill Cornell Medical College and the New York Presbyterian Hospital Todd Rosenblat, Columbia University Medical Center, New York, NY Martha Arellano, Winship Cancer Institute at Emory University Scott R Solomon, The Blood and Marrow Transplant Group of Georgia, Atlanta, GA Jessica K Altman, Francis J Giles, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL Casey O Connell, University of Southern California Norris Comprehensive Cancer Center and Hospital, Los Angeles, CA Marco Gobbi, Azienda Ospedaliera Universitaria San Martino, University of Genoa, Genoa, Italy Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain Arnaud Pigneux, Centre Hospitalier Universitaire de Bordeaux Hôpital Haut Lévêque, Pessac Norbert Vey, L Institut Paoli Calmettes, Marseilles, France Robert Hills, Cardiff University School of Medicine, Cardiff, United Kingdom Tove Flem Jacobsen, Athos Gianella Borradori, Øivind Foss, and Sylvia Vetrhus, Clavis Pharma ASA, Oslo, Norway
    J Clin Oncol 32:1919-26. 2014
    ....
  4. doi request reprint Current treatment of acute myeloid leukemia
    Gail J Roboz
    Leukemia Program, Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, New York 10065, USA
    Curr Opin Oncol 24:711-9. 2012
    ..The objectives of this review are to discuss standard and investigational nontransplant treatment strategies for acute myeloid leukemia (AML), excluding acute promyelocytic leukemia...
  5. pmc Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
    Gail J Roboz
    Leukemia Program, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10065, United States
    Leuk Res 36:407-12. 2012
    ..There were no differences in 30- or 60-day mortality between the two groups...
  6. doi request reprint Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemia
    Gail J Roboz
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Semin Hematol 45:S22-4. 2008
    ..Manuscript has been accepted for publication...
  7. doi request reprint Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia
    Gail J Roboz
    Leukemia Program, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
    Cancer 113:2504-11. 2008
    ..In this study, the authors evaluated the safety and efficacy of arsenic trioxide combined with low-dose cytarabine in untreated patients aged >or=60 years with AML...
  8. doi request reprint Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome
    Gail J Roboz
    Leukemia Program, Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Res 35:522-5. 2011
    ..Mortality within the first 4 weeks was 8%. The regimen was active and had a tolerable extramedullary toxicity profile, but it was cumbersome and intensive compared to other currently available treatments...
  9. doi request reprint Acute myeloid leukemia stem cells: seek and destroy
    Gail J Roboz
    Weill Medical College of Cornell University, The New York Presbyterian Hospital, 520 East 70th Street, New York, NY 10021, USA
    Expert Rev Hematol 2:663-72. 2009
    ..This review will describe bench and translational research in LSCs and discuss how the data should be used to change the direction of developmental therapeutics and clinical trials in AML...
  10. ncbi request reprint Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma
    Gail J Roboz
    Division of Hematology Oncology, Leukemia Program, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Res 31:1141-4. 2007
    ..Our findings suggest that the potential risk of these important complications must be considered in the development of this novel therapeutic strategy in the first-line setting...
  11. ncbi request reprint Treatment of acute myeloid leukemia in older patients
    Gail J Roboz
    Weill Medical College of Cornell University and The New York Presbyterian Hospital, 520 East 70th Street, Starr 340A, New York, NY 10021, USA
    Expert Rev Anticancer Ther 7:285-95. 2007
    ..The role of hematopoietic stem cell transplantation in older patients is under investigation. All patients over 60 years of age with acute myeloid leukemia should be encouraged to participate in a clinical trial if possible...
  12. ncbi request reprint Hematopoietic growth factors in myelodysplastic syndromes
    Victoria S Blinder
    Weill Medical College of Cornell University, Starr Building, Room 340A, 520 East 70th Street, New York, NY 10021, USA
    Curr Hematol Rep 2:453-8. 2003
    ..This paper reviews the role of hematopoietic growth factors in the treatment of MDS...
  13. ncbi request reprint Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia
    Gail J Roboz
    Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, NY 10021, USA
    J Clin Oncol 25:10-5. 2007
    ....
  14. ncbi request reprint Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome
    G J Roboz
    Leukemia Program, Weill Medical College of Cornell University The New York Presbyterian Hospital, New York, NY, USA
    Leukemia 20:952-7. 2006
    ..In conclusion, the MTD of PTK/ZK is 750 mg orally b.i.d. The drug is generally well tolerated and can be given in combination with chemotherapy for patients with MDS and AML...
  15. pmc Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML
    Joseph M Scandura
    Leukemia Program, Weill Cornell Medical College, New York, NY, USA
    Blood 118:1472-80. 2011
    ..We conclude that epigenetic priming of intensive chemotherapy can be safely delivered in an attempt to improve response rates. This trial was registered at www.clinicaltrials.gov as NCT00538876...
  16. pmc Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia
    Ellen K Ritchie
    Leukemia Program, Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY 10065, USA
    Leuk Lymphoma 54:2003-7. 2013
    ..7% with a median OS of 177 days. Extramedullary toxicity was mild and the regimen was well tolerated for ongoing post-remission, outpatient maintenance cycles. Responses were durable for over 1 year...
  17. doi request reprint Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial
    Azra Raza
    St Vincent s Comprehensive Cancer Center, New York, NY, USA
    Leuk Lymphoma 50:1336-44. 2009
    ..In contrast to aggressive conventional chemotherapy, lintuzumab was administered in an ambulatory clinic setting with acceptable toxicity...
  18. doi request reprint First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia
    Eric J Feldman
    Weill Medical College of Cornell University and New York Presbyterian Hospital, 525 East 68th St, New York, NY 10021, USA
    J Clin Oncol 29:979-85. 2011
    ..This phase I dose-escalation trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities, and pharmacokinetics of CPX-351...
  19. ncbi request reprint A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy
    Tsiporah Shore
    Weill Medical College of Cornell University New York Presbyterian Hospital, New York, New York 10021, USA
    Biol Blood Marrow Transplant 12:868-75. 2006
    ....
  20. ncbi request reprint Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia
    Eric J Feldman
    Weill Medical College of Cornell University, 525 E 68th St, New York, NY 10021, USA
    J Clin Oncol 23:4110-6. 2005
    ..In this study, the efficacy of lintuzumab in combination with induction chemotherapy was compared with chemotherapy alone in adults with first relapsed or primary refractory acute myeloid leukemia (AML)...
  21. doi request reprint Levels of care: defining best supportive care in elderly patients with acute myeloid leukemia
    Ellen K Ritchie
    Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY 10065, USA
    Curr Hematol Malig Rep 5:95-100. 2010
    ..Because it has never been shown that BSC as a sole therapeutic approach is kinder, less expensive, or better for older AML patients, it should be reserved for select clinical situations...
  22. doi request reprint Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies
    Michael J Satlin
    Department of Medicine, Weill Cornell Medical College, New York, NY, USA
    Leuk Lymphoma 54:799-806. 2013
    ..New diagnostic, therapeutic and preventive strategies for CRE infections in this vulnerable population are needed...
  23. ncbi request reprint Standardizing the initial evaluation for myelodysplastic syndromes
    Danielle Marshall
    Department of Medicine, Weill Medical College of Cornell University, 515 E 71st Street, S Building, Room S262, New York, NY, 10021, USA
    Curr Hematol Malig Rep 8:361-9. 2013
    ....
  24. doi request reprint Pregnancy in a woman with chronic neutrophilic leukemia
    Jolyn Taylor
    Department of Obstetrics and Gynecology, New York Presbyterian Hospital Weill Cornell Medical Center, New York, New York 10065, USA
    Obstet Gynecol 121:457-60. 2013
    ..Chronic neutrophilic leukemia is a rare myeloproliferative disorder in women of reproductive age...
  25. ncbi request reprint Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase
    Francis J Giles
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, P O Box 428, Houston, TX 77030, USA
    Leuk Res 27:1091-6. 2003
    ..Grade 3 or 4 toxicities included stomatitis (4%), hand-foot syndrome (18%), and skin rash (12%). Four patients (13%) responded. Troxacitabine-based combinations merit study in IM-resistant CML...
  26. ncbi request reprint Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma
    John D Roberts
    Massey Cancer Center, Virginia Commonwealth University, Medical College of Virginia, Richmond, VA 23298, USA
    Clin Cancer Res 12:5809-16. 2006
    ..We undertook a phase I study to identify appropriate schedules and doses of bryostatin 1 and fludarabine to be used in phase II studies...
  27. ncbi request reprint PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia
    Francis J Giles
    The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 31:891-7. 2007
    ..One (3%) and five (17%) patients achieved complete remission and clinical improvement, respectively. PTK/ZK has modest activity in patients with MMM...
  28. ncbi request reprint Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
    Francois Guilhot
    Clinical Research Centre, Centre Hospitalier et Universitaire La Miletrie, Poitiers, France
    Blood 109:4143-50. 2007
    ..Further follow-up is warranted. This trial was registered at www.clinicaltrials.gov as #CA180005...